Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: SAMSCA

Summary for Tradename: SAMSCA

Suppliers: see list1
patent expirations by year for

Clinical Trials for: SAMSCA

Effects of Tolvaptan in Healthy Adults
Status: Recruiting Condition: Healthy

A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
Status: Recruiting Condition: Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)

Effect of the Diuretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)
Status: Recruiting Condition: Nephropathy

Post-Authorisation Safety Study of Samsca (Tolvaptan) Used in Routine Medical Practice
Status: Active, not recruiting Condition: SIADH; Non-SIADH Hyponatremia; Non-Hyponatremia

Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
Status: Completed Condition: Ascites; Hepatic Cirrhosis

Tolvaptan for Ascites in Cirrhotic Patients
Status: Recruiting Condition: Ascites; Cirrhosis

Bioavailability Study Comparing Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed Intact
Status: Completed Condition: Healthy

Tolvaptan in Hyponatremic Cancer Patients
Status: Completed Condition: Advanced Cancers

Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
Status: Terminated Condition: Hyponatremia; Dilutional Hyponatremia; Inappropriate ADH Syndrome

8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Status: Completed Condition: Autosomal Dominant Polycystic Kidney Disease

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Otsuka America Pharm
TABLET;ORAL022275May 19, 2009DISCNNo<disabled><disabled>
Otsuka America Pharm
TABLET;ORAL022275May 19, 2009DISCNNo5,258,510<disabled>YY<disabled>
Otsuka America Pharm
TABLET;ORAL022275May 19, 2009DISCNNo5,753,677<disabled><disabled>
Otsuka America Pharm
TABLET;ORAL022275May 19, 2009DISCNNo8,501,730<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: SAMSCA

Drugname Dosage Strength RLD Submissiondate
tolvaptanTablets15 mg and 30 mgSamsca9/23/2013

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology